Cantor Fitzgerald analyst Alethia Young raised her price target for Alnylam Pharmaceuticals to $176 from $159 saying the company reported a "very clean" positive top-line readout for lumasiran. The analyst finds it notable that lumasiran is the company's fourth pivotal RNAi readout in the past two years and will be the third wholly owned commercial product after Onpattro and recently approved Givlaari. She thinks the positive update adds to Alnylam's recent momentum heading into 2020, as its "rapid transition to a full fledged commercial company with a robust pipeline continues." Young reiterates an Overweight rating on Alnylam.

ProQR Therapeutics (PRQR) announced the Annual General Meeting, AGM, of Shareholders will take place on Wednesday, May 22, 2024 at the offices of Allen & Overy LLP, in Amsterdam, the Netherlands. As part of the AGM, Martin Maier, PhD, is nominated for appointment as a non-executive Board Member for a period of four years. Dr. Maier is Senior Vice President Research heading the Oncology group at Alnylam Pharmaceuticals (ALNY).